381 related articles for article (PubMed ID: 20693595)
1. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
2. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
3. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
4. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity.
Sarda P; Sharma SK; Mohan A; Makharia G; Jayaswal A; Pandey RM; Singh S
Indian J Med Res; 2009 Jan; 129(1):64-7. PubMed ID: 19287059
[TBL] [Abstract][Full Text] [Related]
5. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
7. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
[TBL] [Abstract][Full Text] [Related]
8. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.
Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO
Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986
[TBL] [Abstract][Full Text] [Related]
9. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.
Ungo JR; Jones D; Ashkin D; Hollender ES; Bernstein D; Albanese AP; Pitchenik AE
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1871-6. PubMed ID: 9620920
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia.
Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M
Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542
[TBL] [Abstract][Full Text] [Related]
11. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.
Sharma SK; Balamurugan A; Saha PK; Pandey RM; Mehra NK
Am J Respir Crit Care Med; 2002 Oct; 166(7):916-9. PubMed ID: 12359646
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.
Pande JN; Singh SP; Khilnani GC; Khilnani S; Tandon RK
Thorax; 1996 Feb; 51(2):132-6. PubMed ID: 8711642
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
[TBL] [Abstract][Full Text] [Related]
15. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity.
Warmelink I; ten Hacken NH; van der Werf TS; van Altena R
Br J Nutr; 2011 Feb; 105(3):400-8. PubMed ID: 20875187
[TBL] [Abstract][Full Text] [Related]
16. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.
Baghaei P; Tabarsi P; Chitsaz E; Saleh M; Marjani M; Shemirani S; Pooramiri MV; Kazempour M; Farnia P; Fahimi F; Mansouri D; Masjedi M
Am J Ther; 2010; 17(1):17-22. PubMed ID: 19535968
[TBL] [Abstract][Full Text] [Related]
17. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Satyaraddi A; Velpandian T; Sharma SK; Vishnubhatla S; Sharma A; Sirohiwal A; Makharia GK; Sinha S; Biswas A; Singh S
Int J Tuberc Lung Dis; 2014 Feb; 18(2):188-95, i-iii. PubMed ID: 24429311
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
Sharma SK; Jha BK; Sharma A; Sreenivas V; Upadhyay V; Jaisinghani C; Singla R; Mishra HK; Soneja M
Int J Tuberc Lung Dis; 2014 May; 18(5):588-93. PubMed ID: 24903797
[TBL] [Abstract][Full Text] [Related]
19. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
[TBL] [Abstract][Full Text] [Related]
20. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
